146 related articles for article (PubMed ID: 16575475)
1. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma.
Elbl L; Vasova I; Tomaskova I; Jedlicka F; Navratil M; Pospisil Z; Vorlicek J
Neoplasma; 2006; 53(2):174-81. PubMed ID: 16575475
[TBL] [Abstract][Full Text] [Related]
2. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Nousiainen T; Vanninen E; Jantunen E; Remes J; Ritanen E; Vuolteenaho O; Hartikainen J
Clin Sci (Lond); 2001 Dec; 101(6):601-7. PubMed ID: 11724646
[TBL] [Abstract][Full Text] [Related]
4. [The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients].
Medvedev PV; Nikitin EA; Pivnik AV
Ter Arkh; 2000; 72(7):38-42. PubMed ID: 10983319
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens.
Elbl L; Vasova I; Kral Z; Tomaskova I; Smardova L; Wagnerova B; Jedlicka F; Vorlicek J
J Chemother; 2006 Apr; 18(2):199-208. PubMed ID: 16736890
[TBL] [Abstract][Full Text] [Related]
6. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
Schmitt CJ; Dietrich S; Ho AD; Witzens-Harig M
Ann Hematol; 2012 Mar; 91(3):391-7. PubMed ID: 21850390
[TBL] [Abstract][Full Text] [Related]
7. [Changes in left ventricular function during chemotherapy with doxorubicin].
Elbl L; Chaloupka V; Vásová I; Kiss I; Jancík J; Vorlícek J; Navrátil M
Vnitr Lek; 1999 Jul; 45(7):395-402. PubMed ID: 11045157
[TBL] [Abstract][Full Text] [Related]
8. Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults.
Elbl L; Vasova I; Tomaskova I; Jedlicka F; Kral Z; Navratil M; Smardova L; Wagnerova B; Vorlicek J
Leuk Lymphoma; 2006 May; 47(5):843-51. PubMed ID: 16753868
[TBL] [Abstract][Full Text] [Related]
9. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.
Limat S; Daguindau E; Cahn JY; Nerich V; Brion A; Perrin S; Woronoff-Lemsi MC; Deconinck E
J Clin Pharm Ther; 2014 Apr; 39(2):168-74. PubMed ID: 24384030
[TBL] [Abstract][Full Text] [Related]
11. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma.
Dann EJ; Epelbaum R; Avivi I; Ben Shahar M; Haim N; Rowe JM; Blumenfeld Z
Hum Reprod; 2005 Aug; 20(8):2247-9. PubMed ID: 15817583
[TBL] [Abstract][Full Text] [Related]
12. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma.
Szmit S; Jurczak W; Zaucha JM; Drozd-Sokołowska J; Spychałowicz W; Joks M; Długosz-Danecka M; Torbicki A
J Am Soc Hypertens; 2014 Nov; 8(11):791-9. PubMed ID: 25455004
[TBL] [Abstract][Full Text] [Related]
13. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.
Limat S; Demesmay K; Voillat L; Bernard Y; Deconinck E; Brion A; Sabbah A; Woronoff-Lemsi MC; Cahn JY
Ann Oncol; 2003 Feb; 14(2):277-81. PubMed ID: 12562656
[TBL] [Abstract][Full Text] [Related]
14. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
15. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
Hequet O; Le QH; Moullet I; Pauli E; Salles G; Espinouse D; Dumontet C; Thieblemont C; Arnaud P; Antal D; Bouafia F; Coiffier B
J Clin Oncol; 2004 May; 22(10):1864-71. PubMed ID: 15143078
[TBL] [Abstract][Full Text] [Related]
16. [Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy].
Elbl L; Vásová I; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Vorlícek J
Vnitr Lek; 2006 Apr; 52(4):328-38. PubMed ID: 16755989
[TBL] [Abstract][Full Text] [Related]
17. Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma.
Kilickap S; Yavuz B; Aksoy S; Sahiner L; Dincer M; Harputluoglu H; Erman M; Aytemir K; Tokgozoglu L; Barista I
Med Oncol; 2008; 25(4):437-42. PubMed ID: 18415035
[TBL] [Abstract][Full Text] [Related]
18. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Nousiainen T; Jantunen E; Vanninen E; Hartikainen J
Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452
[TBL] [Abstract][Full Text] [Related]
19. [Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
Li QC; Yuan XL; Wang YF; Zou DH; Zhao YZ; Qiu LG
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):254-7. PubMed ID: 18361837
[TBL] [Abstract][Full Text] [Related]
20. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
